Investor Presentation First Nine Months of 2022
23
Investor presentation First nine months of 2022
Sales growth of 16%, driven by the GLP-1 portfolio for diabetes
and obesity treatment
Novo NordiskⓇ
DKK
billion
50
by therapy
Reported sales
CAGR1: 8.1%
Novo Nordisk reported quarterly sales
Reported sales for the first
nine months of 2022
Reported sales and growth breakdown for
the first nine months of 2022
40
40
Rare Other
Rare endocrine rare
blood disorders disease
Therapy
Sales
(mDKK)
Growth
Share of
growth
Total GLP-12
59,019
44%
101%
Long-acting insulin³
12,839
-10%
-8%
disorders
1%
Premix insulin4
8,219
-10%
-5%
4%
-3.4%¹
7%
Fast-acting insulin5
12,992
-8%
-6%
Obesity
30
Human insulin
2.1%1
6,216
-18%
-8%
care
9%
Total insulin
40,266
-11%
-27%
1.8%¹
Other Diabetes care
2,512
-15%
-3%
20
9.4 %1
Total Diabetes care
Obesity care?
101,797
14%
71%
11,376
75%
27%
10
79%
Diabetes care
Diabetes and Obesity care
Rare blood disorders
113,173
18%
99%
8,825
6%
3%
0
Q3
Other rare disease
2012
Rare endocrine disorders
Q3
2022
Rare endocrine disorders⁹
Other Rare disease10
Rare disease
5,536
-6%
-2%
1,328
7%
1%
15,689
2%
1%
Rare blood disorders
Diabetes and Obesity care
Sales of DKK 128.9 billion
(+26%)
Total
128,862
16%
100%
1 CAGR for 10-year period; 2 Comprises Victoza®, Ozempic®, Rybelsus®; 3 Comprises TresibaⓇ, XultophyⓇ and Levemir®; 4 Comprises RyzodegⓇ and Novo MixⓇ; 5 Comprises FiaspⓇ and NovoRapidⓇ; 6 Primarily NovonormⓇ, needles and GlucaGen® HypoKitⓇ;
7 Comprises SaxendaⓇ and Wegovy®: 8 Comprises NovoSeven®, Novo Eight®, NovoThirteen®, Refixia®, and EsperoctⓇ: 9 Comprises Norditropin and Macrilen TM; 10 Primarily Vagifem® and ActivelleⓇ
Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 26%; Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.View entire presentation